FY2027 Earnings Estimate for Biogen Issued By William Blair

Biogen Inc. (NASDAQ:BIIB - Free Report) - Equities research analysts at William Blair decreased their FY2027 EPS estimates for Biogen in a research report issued on Wednesday, April 23rd. William Blair analyst M. Minter now expects that the biotechnology company will earn $16.77 per share for the year, down from their prior estimate of $17.41. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. William Blair also issued estimates for Biogen's FY2028 earnings at $17.66 EPS and FY2029 earnings at $18.03 EPS.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.43 by $0.01. Biogen had a net margin of 16.87% and a return on equity of 14.98%.

BIIB has been the subject of a number of other reports. The Goldman Sachs Group decreased their price objective on Biogen from $219.00 to $197.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. HSBC cut Biogen from a "buy" rating to a "hold" rating and set a $118.00 price objective for the company. in a research note on Monday. HC Wainwright decreased their price objective on Biogen from $300.00 to $241.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. Sanford C. Bernstein began coverage on Biogen in a research note on Tuesday, February 11th. They set a "market perform" rating and a $160.00 price objective for the company. Finally, Truist Financial decreased their target price on Biogen from $210.00 to $199.00 and set a "buy" rating for the company in a research note on Tuesday. Twenty research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $201.93.

Biogen Price Performance

Shares of BIIB stock traded down $0.12 during trading hours on Friday, reaching $120.05. 386,914 shares of the company were exchanged, compared to its average volume of 1,342,250. The stock's fifty day moving average is $131.78 and its two-hundred day moving average is $148.18. Biogen has a fifty-two week low of $110.04 and a fifty-two week high of $238.00. The company has a market cap of $17.57 billion, a price-to-earnings ratio of 10.73, a P/E/G ratio of 1.51 and a beta of 0.06. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.35 and a quick ratio of 0.90.

Insider Activity

In other news, Director Stephen A. Sherwin sold 8,760 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $150.02, for a total value of $1,314,175.20. Following the completion of the sale, the director now directly owns 11,318 shares of the company's stock, valued at $1,697,926.36. This trade represents a 43.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 0.16% of the company's stock.

Institutional Trading of Biogen

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of Biogen by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 16,748,875 shares of the biotechnology company's stock valued at $2,561,238,000 after buying an additional 70,368 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Biogen by 2.3% in the fourth quarter. Geode Capital Management LLC now owns 3,695,476 shares of the biotechnology company's stock valued at $563,709,000 after buying an additional 82,456 shares during the last quarter. Pacer Advisors Inc. increased its stake in shares of Biogen by 13,574.7% during the fourth quarter. Pacer Advisors Inc. now owns 2,667,531 shares of the biotechnology company's stock worth $407,919,000 after purchasing an additional 2,648,024 shares during the period. Norges Bank bought a new position in shares of Biogen during the fourth quarter worth approximately $355,569,000. Finally, Invesco Ltd. increased its stake in shares of Biogen by 30.6% during the fourth quarter. Invesco Ltd. now owns 2,128,807 shares of the biotechnology company's stock worth $325,537,000 after purchasing an additional 499,074 shares during the period. 87.93% of the stock is owned by institutional investors and hedge funds.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.